Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy

Biomedicine and Pharmacotherapy

Volumn 59, Issue 1-2, 2005, Pages 15-19

  Galetta, F ^a   Franzoni, F ^a   Magagna, A ^a   Femia, F R ^a   Pentimone, F ^a   Santoro, G ^a   Carpi, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Arterial hypertension; Left ventricular hypertrophy; Nebivolol; QT dispersion

Indexed keywords

NEBIVOLOL;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; QT DISPERSION; STATISTICAL SIGNIFICANCE;

EID: 14644401064     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2004.05.016     Document Type: Article

References (31)

1. M. Zabel, S. Portnoy, and M.R. Franz Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study J. Am. Coll. Cardiol. 25 3 1995 746 752
2. K. Ichkhan, J. Molnar, and J. Somberg Relation of left ventricular mass and QT dispersion in patients with systematic hypertension Am. J. Cardiol. 79 1997 508 511
3. F. Galetta, F. Franzoni, G. Santoro, F. Prattichizzo, F.R. Femia, F. Pastine, and F. Pentimone QT dispersion in elderly athletes with left ventricular hypertrophy Int. J. Sports Med. 24 2003 233 237
4. M. Galinier, S. Balanescu, J. Fourcade, M. Dorobanta, J.P. Albenque, and P. Massabuau Prognostic value of arrhythmogenic markers in systemic hypertension Eur. Heart J. 18 1997 1484 1491
5. M. Pye, A.C. Quinn, and S.M. Cobbe QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br. Heart J. 71 1994 511 514
6. E.A. Karpanou, G.P. Vyssoulis, A. Psichogious, C. Malakou, E.A. Kyrozi, and D.V. Cokkinos Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension Am. Heart J. 136 1998 765 768
7. L. Oikarinen, M.S. Nieminen, L. Toivonen, M. Viitasalo, K. Wachtell, and V. Papademetriou LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) study Am. Heart. J. 145 5 2003 919 925
8. P.O. Lim, M. Nys, A.A. Naas, A.D. Struthers, M. Osbakken, and T.M. MacDonald Irbesartan reduces QT dispersion in hypertensive individuals Hypertension 33 2 1999 713 718
9. C.E. Bonnar, A.P. Davie, L. Caruana, L. Fenn, S.A. Ogston, and J.J. McMurray QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion Heart 81 1999 297 302
10. A. Yildirir, E. Sade, L. Tokgozoglu, and A. Oto The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure Eur. J. Heart Fail. 3 2001 717 721
11. S.I. Fesmire, L.G. Marcoux, D.S. Lyyski, M.K. Sprague, H.L. Kennedy, and E.J. Eichhorn Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy Am. J. Cardiol. 84 1999 350 354
12. D. Puljevic, A. Smalcelj, Z. Durakovic, and V. Goldner The influence of atenolol and propafenone on QT interval dispersion in patients 3:months after myocardial infrarction Int. J. Clin. Pharmacol. Ther. 5 1997 381 384
13. F. Leonardo, G. Fragasso, G.M. Rosano, P. Pagnotta, and S.L. Chierchia Effect of atenolol on QT interval and dispersion in patients with syndrome X Am. J. Cardiol. 80 1997 789 790
14. D.J. Sahn, A. DeMaria, J. Kisslo, and A. Weyman The committee on M-mode standardization of the American society of echocardiography: recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements Circulation 58 1978 1072 1083
15. R.B. Devereux, and N. Reichek Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method Circulation 55 1977 613 618
16. J.R. Gonzalez-Juanatey, J.M. Garcia-Acuna, A. Pose, A. Varela, C. Calvo, and J. Cabezas-Cerrato Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril Am. J. Cardiol. 81 1998 170 174
17. J. Mayet, M. Shahi, K. McGrath, N.R. Poulter, P.S. Sever, and R.A. Foale Left ventricular hypertrophy and QT dispersion in hypertension Hypertension 28 5 1996 791 796
18. C.S. Barr, A.A. Naas, M. Fenwick, and A.D. Struthers Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease Am. J. Cardiol. 79 3 1997 328 333
19. M. Akbulut, Y. Ozbay, E. Ilkay, I. Karaca, and N. Arslan Effects of spironolactone and metoprolol on QT dispersion in heart failure Jpn. Heart J. 44 2003 681 692
20. F. Franzoni, E. Mataloni, R. Femia, and F. Galetta Effect of oral potassium supplementation on QT dispersion in anorexia nervosa Acta Paediatr. 91 2002 653 656
21. A. Cupisti, F. Galetta, R. Caprioli, E. Morelli, G. Tintori, and F. Franzoni Potassium removal increases the QTc interval dispersion during hemodialysis Nephron 82 1999 122 126
22. M. Pagani, and D. Lucini Autonomic dysregulation in essential hypertension: insight from heart rate and arterial pressure variability Auton. Neurosci. 90 2001 76 82
23. J.A. Abildskov Adrenergic effects of the QT interval on the electrocardiogram Am. Heart J. 92 1976 210 216
24. K. Malmqvist, T. Kahan, M. Edner, and L. Bergfeldt Comparison of actions of irbesartan vs. atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish irbesartan left ventricular hypertrophy investigation vs. atenolol (SILVHIA) Am. J. Cardiol. 90 2002 1107 1112
25. W.J. Kakoki, Y. Hirota, H. Nishimatsu, Y. Suzuki, D. Nagata, and K. Suzuki Effects of vasodilatatory beta-adrenoceptor antagonista on endothelium-derived nitric oxide release in rat kidney Hypertension 33 1999 467 471
26. J.R. Cockcroft, P.J. Chowienczyk, S.E. Brett, C.P.L.H. Chen, A.G. Dupont, and L. Van Nueten Nebivolol vasodilates human foream vasculature: evidence for an l-arginine/NO-dependent mechanism J. Pharmacol. Experiment Therapeutics 274 1995 1067 1071
27. T. Wisenbaugh, I. Katz, J. Davis, R. Essop, J. Skoularigis, and S. Middlemost Long-term (3:month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomiopathy J. Am. Coll. Cardiol. 21 1993 1094 1100
28. R. Troost, E. Schwedhelm, S. Rojczyk, D. Tsikas, and J.C. Frolich Nebivolol decreases systemic oxidative stress in healthy volunteers Br. J. Clin. Pharmacol. 50 2000 377 379
29. B.R. Brehm, D. Bertsch, J. Von Fallois, and S.C. Wolf Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells J. Cardiovasc. Pharmacol. 36 2000 S401 S403
30. M.R. Franz, K. Bargheer, A. Costard-Jackle, D.C. Miller, and P.R. Lichtlen Human ventricular repolarization and T wave genesis Prog. Cardiovasc. Dis. 33 1991 369 384
31. P.M. Janssen, O. Zeitz, and G. Hasenfuss Transiet and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol Eur. J. Pharmacol. 366 1999 223 232